68Ga-PSMA PET/CT与纳米氧化铁增强MRI诊断前列腺癌淋巴结转移的头对头比较
该回顾性研究纳入45例原发或复发前列腺癌患者,均在3周内接受68Ga-PSMA PET/CT与纳米氧化铁增强MRI(nano-MRI),独立比较可疑淋巴结的大小、解剖位置与怀疑程度。nano-MRI检出显著更多可疑淋巴结(160枚/33例 vs 71枚/25例,P<0.001),且检出的淋巴结平均更小(5.3 mm vs 6.0 mm,P=0.006);两种方法在盆腔各解剖区域均可发现可疑淋巴结,提示nano-MRI可能作为PSMA PET/CT的补充。
要点
- nano-MRI检出可疑淋巴结160枚(33例),显著多于PSMA PET/CT的71枚(25例),P<0.001。
- 仅nano-MRI检出108枚(60%),仅PSMA PET/CT检出19枚(11%),两者共同检出52枚(29%)。
- nano-MRI检出的可疑淋巴结平均更小(5.3 mm vs 6.0 mm,P=0.006),怀疑程度中位数无显著差异。
核心结论
- 两种方法各自检出对方遗漏的可疑淋巴结,nano-MRI在检出更小可疑淋巴结方面似乎更优,可能作为PSMA PET/CT的补充。
- 不同检查结果对应的临床意义尚未明确,作者鼓励进一步研究其互补应用。
研究设计与样本
- 回顾性研究,共纳入45例前列腺癌患者,其中原发8例、复发36例。
- 所有患者于2015年10月至2017年7月间在3周内于同一机构按本地临床方案完成68Ga-PSMA PET/CT与nano-MRI。
- 所有扫描由经验丰富的核医学医师与放射科医师独立分析,比较时不参考参考标准。
主要发现
- 共识别179枚可疑淋巴结;nano-MRI在33例中检出160枚,PSMA PET/CT在25例中检出71枚,每例检出数差异显著(P<0.001)。
- 108枚(60%)仅由nano-MRI检出,19枚(11%)仅由PSMA PET/CT检出,52枚(29%)两者均检出。
- nano-MRI检出的可疑淋巴结平均大小为5.3 mm,显著小于PSMA PET/CT的6.0 mm(P=0.006)。
- 两种方法检出的可疑淋巴结怀疑程度中位数无显著差异,且均在盆腔所有解剖区域发现可疑淋巴结。
关键数值与推荐
- 每例检出可疑淋巴结数:nano-MRI显著多于PSMA PET/CT(P<0.001)。
- 可疑淋巴结平均大小:nano-MRI 5.3 mm vs PSMA PET/CT 6.0 mm(P=0.006)。
- 仅nano-MRI检出108枚(60%),仅PSMA PET/CT检出19枚(11%),两者均检出52枚(29%)。
临床怎么用
- nano-MRI可能作为PSMA PET/CT的补充,用于检出更小的可疑淋巴结。
- 两种方法结果不一致时的临床处理意义尚未确立,需进一步研究互补应用。
局限性
- 为回顾性研究,比较未参考参考标准,不同检查结果的临床意义尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate assessment of lymph node (LN) metastases in prostate cancer (PCa) patients is critical for prognosis and patient management. Both prostate-specific membrane antigen (PSMA) PET/CT and ferumoxtran-10 nanoparticle-enhanced MRI (nano-MRI) are imaging modalities with high potential to identify LN metastases in PCa patients. The aim of this study was to compare the results of these imaging technologies in terms of characteristics and anatomic localization of suspicious LNs in order to assess the feasibility of their complementary use for imaging in PCa patients. Methods: In total, 45 patients with either primary PCa (n = 8) or recurrence (n = 36) were included in this retrospective study. All patients underwent both 68Ga-PSMA PET/CT and nano-MRI between October 2015 and July 2017 within 3 wk. Both scans were performed at the same institution according to local clinical protocols. All scans were analyzed independently by experienced nuclear medicine physicians and radiologists. The size, anatomic location, and level of suspicion were determined for all visible LNs. Subsequently, the findings from 68Ga-PSMA PET/CT and nano-MRI were compared without respect to a reference standard. Results: In total, 179 suspicious LNs were identified. Significantly more suspicious LNs per patient were detected by nano-MRI (P < 0.001): 160 were identified in 33 patients by nano-MRI, versus 71 in 25 patients by 68Ga-PSMA PET/CT. Of all suspicious LNs, 108 were identified only by nano-MRI (60%), 19 (11%) only by 68Ga-PSMA PET/CT, and 52 (29%) by both methods. The mean size of the suspicious LNs as identified by nano-MRI was significantly smaller (5.3 mm) than that by 68Ga-PSMA PET/CT (6.0 mm; P = 0.006). The median level of suspicion did not differ significantly. Both modalities identified suspicious LNs in all anatomic regions of the pelvis. Conclusion: Both modalities identified suspicious LNs that were missed by the other. Both modalities identified suspicious LNs in all anatomic regions of the pelvis; however, nano-MRI appeared to be superior in detecting smaller suspicious LNs. These findings suggest that nano-MRI has a potential role as a complement to PSMA PET/CT. However, since the clinical implications of the different results are not well established yet, further investigation of this complementary use is encouraged.
引用
- Schilham MGM, Zamecnik P, Privé BM, et al. Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients. J Nucl Med. 2021. PMID: 33517328. doi:10.2967/jnumed.120.258541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。